Cell therapy companies have been rapidly populating over the past few years, making the market a high-value, fast-growth market. To keep you in the loop, we have released new coverage of industry events. Check it out and let me know what you think? AllCells, LLC specializes in biologically relevant, high quality primary cells to enable drug discovery, development, and manufacturing of cell therapies. Recently, I had the honor of interviewing Dr. Jay Tong, President and CEO of AllCells. In this interview, we discuss AllCells history, its leadership in blood donor cell collections and hematologic tissue products and the recent opening of its newest facility in Boston, Massachusetts. We also explore the company’s long-term goals and expansion into the cell therapy development space.
Astellas and Universal Cells Collaborate to Utilize Universal Donor Cell Technology
Astellas Pharma Inc. and Universal Cells, Inc. announced that Astellas Institute for Regenerative Medicine (“AIRM”) and Universal Cells have entered into an exclusive worldwide license agreement to research, develop and commercialize a novel cell therapy for an undisclosed indication. The collaboration will utilize Universal Cells’ Universal Donor Cell technology to create cell therapy products that can be administered to any recipient without the need for Human Leukocyte Antigen (HLA) matching.
Attend the IOF's annual conference titled The Orthobiologic Singularity—a paradigm shift that will take orthopedic medicine from invasive to regenerative—and learn how to position yourself to benefit. The agenda will include an all start line-up of presenters offering didactic lectures, interactive discussions, panel discussions, debates, and Q&A sessions. There will also be accredited hands-on cadaver labs, including the world’s first certification for Percutaneous Regenerative Arthroscopy for the Knee and Bone Marrow/Mini-Lipo Aspiration & Basics of Performing and Understanding Nucleated Cell Counting.
The Inside Scoop on Biostage, a World Leader in Bioengineered Organs
Biostage is a clinical-stage company specializing in bioengineered organ implants to treat cancer and other conditions involving the esophagus, bronchus and trachea. In August 2017, the company transplanted its esophageal implant product into its first patient worldwide, a 75-year old man with cancer. In this interview with Jim McGorry, President and CEO of Biostage, we discuss the company’s vision, its research partnerships, clinical trial strategy, and five-year goals.
Dental Stem Cell Trends in the Scientific Literature
Dental pulp is the soft living tissue inside a tooth that contains mesenchymal stem cells (MSCs). The ideal time to harvest dental stem cells is when children lose their deciduous (baby) teeth, either through natural loss or extraction. An important way to gauge progress within the dental stem cell market is to consider trend rate data for scientific publications over a trailing ten-year period.
Do You Know the 5 Types of Dental Stem Cells?
While MSCs from dental pulp stem cells are only being used only in laboratory settings at this time, there is huge potential for the cells to be used for regenerative medicine applications, because MSCs from other sources are being explored in more than 600 clinical trials worldwide. Read this article to learn the five types of dental stem cells, their unique characteristics, and how each is sourced.
Key Competitors in the Dental Stem Cell Storage Market [Market Brief + Database]
While the dental stem cell storage market is an early-stage market, new competitors are quickly entering it, with the United States, UK, and India leading the way as “hot spots” for market activity. This 10-page brief identifies global competitors offering dental stem cell storage services, top countries for dental stem cell storage, trends in the scientific literature, a timeline of key industry events, and more.
Cell Therapy Companies – CAR-T, CAR-NK, Stem Cells, Direct Reprogramming
Cell therapy companies have been rapidly populating over the past few years, making the cell therapy market a high-value, fast-growth market. Key drivers for the market include high rates of cell therapy clinical trials, accelerated pathways for cell therapy product approvals, new technologies to support cell therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.
Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts
Mustang Bio, a Fortress Biotech, Inc. company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced that it has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical development and commercialization of the company’s CAR T product candidates.
Cell Therapy CDMOs – Role of Contract Manufacturing for Cell Therapies
Among cell therapy companies, the pressure for manufacturing innovation and optimization can incentivize them to seek third-party partners who possess technical, manufacturing, and regulatory expertise, such as cell therapy contract and development manufacturing organizations (CDMOs). Currently, there are more than two dozen cell therapy CDMOs specializing in manufacturing and clinical trial support for cell therapy companies.
This 12-page guide takes the complex global environment for cellular therapeutics and synthesizes it into a clear and concise market brief. Over the past few years, the regulatory landscape for cell therapy development has grown increasingly complex. There are now accelerated pathways for advanced therapy medicinal products (ATMPs) in several countries worldwide, including the U.S., Japan, and South Korea.
Ncardia to Host First Annual Applications Workshop in Cologne, Germany
Ncardia is hosting its first annual Applications Workshop (Nov. 29th-Dec. 1st) in Cologne, Germany. The speakers, coming from both Pharma partners and key academia labs, will highlight the use of Ncardia's human iPSC-derived products within their field of profession. The demonstrations will show the performance of cells in applications such as MEA, contractile cell force measurement, impedance analysis and calcium transient measurement, as well as fatty acid metabolism and optogenetics.
Cell Therapy Industry Database – Featuring 150+ Cell Therapy Companies Worldwide
On the heels of CAR-T cell therapy approvals by Novartis (Kymriah) and Kite Pharma (Yescarta), this database features 150+ cell therapy companies worldwide. These are companies developing cell-based products for therapeutic use. The database was developed in-house for our own purposes, but we have had more and more clients requesting access to it. For a limited-time only, you can claim the database for only $39 and have access for life.
Cord Blood Banking for Twins – Is There Enough for Both Babies?
When parents have twins, they often choose to bank the cord blood of both twins for a variety of reasons. To see if and how the volume and the viability of collections are affected by two or more babies, Cryo-Cell International studied its cord blood collection data from the last 300 multiple births and the last 10,000 single births. It chose these numbers as a representation of the approximately three percent of births that result in two or more offspring.
Newswire: 2018 Global Cord Blood Banking Industry Report
BioInformant, the first and only market research firm to specialize in the stem cell industry, announces the release of its “2018 Global Cord Blood Banking Industry Report.” The 265-page report reveals key forces affecting the industry, presenting trend rate data for cord blood and tissue clinical trials, patents, grants, and scientific publications. It reveals public and private storage counts for cord blood and tissue on a global basis, as well as market size metrics for the public and private sectors, with five-year projections through 2022.
Be Great,
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. Have stem cell news to share? Hit "reply" to this email to send it to me.
|
|
|
